Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Banerjee, et al.
The addition of ASA to BEV+ATE did not improve efficacy. Relative to BEV or ATE(+/-ASA) arms, the BEV+ATE combinations numerically improved PFS and TFST and merits further exploration. Translational analyses are ongoing to identify biomarkers of clinical benefit.
Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study.
Colombo, et al.
INTERMITTENT RELA + nab-pac improved PFS and had a favorable safety profile in recurrent platinum-resistant and/or platinum-refractory ovarian cancer patients.
ORIGINAL ARTICLE IN NEJM:
N. Colombo and Others
Randomised Phase II Trial of Olaparib compared to weekly paclitaxel or Olaparib plus Cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
Nicum, et al.
The OCTOVA trial demonstrated that the combination of O+C showed greater efficacy than O alone, but we did not find evidence that wP was inferior to O in women with multiply relapsed OC.
Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
Pujade-Lauraine, et al.
The OReO/ENGOT Ov-38 trial is the first to provide data on PARPi rechallenge in PSR OC pts. The trial met its primary PFS endpoint. Maintenance O provided a significant improvement in PFS vs P, irrespective of BRCAm status. A proportion of pts derived clinically relevant long-term benefit. Safety was consistent with the known profile of O.